Compare FirstEnergy Corp. (FE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.06B), while State Street SPDR S&P Biotech ETF trades at $158.17. The key difference: FirstEnergy Corp. pays a 3.98% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, FirstEnergy Corp. nearer its low. Which is the better fit depends on your goals.
| FE | XBI | |
|---|---|---|
Market Cap | $27.06B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $51.91 | $164.28 |
52-Week Low | $42.83 | $86.92 |
Enterprise Value | $55.98B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
